title: MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis.
abstract: BACKGROUND
  Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers.
  
  
  OBJECTIVE
  We aimed to explore miRNAs potential as blood biomarkers for psoriasis.
  
  
  METHODS
  Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls.
  
  
  RESULTS
  We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH=1.63, P<0.01; FCH=2.18, P<0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASIscore (r=0.46, P<0.05; r=0.55, P<0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC)=0.80, miR-143: AUC=0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis.
  
  
  CONCLUSIONS
  We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
authors.affiliation: Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark; LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark. Electronic address: mabelo01@geh.regionh.dk.
authors.forename: Marianne B
authors.initials: MB
authors.lastname: Løvendorf
authors.affiliation: LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.
authors.forename: John R
authors.initials: JR
authors.lastname: Zibert
authors.affiliation: Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark.
authors.forename: Mette
authors.initials: M
authors.lastname: Gyldenløve
authors.affiliation: LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark.
authors.forename: Mads A
authors.initials: MA
authors.lastname: Røpke
authors.affiliation: Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, 2900 Hellerup, Denmark.
authors.forename: Lone
authors.initials: L
authors.lastname: Skov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D016022:Case-Control Studies; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D005819:Genetic Markers; D005820:Genetic Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D011237:Predictive Value of Tests; D011565:Psoriasis / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005819:Genetic Markers; D007166:Immunosuppressive Agents; D008727:Methotrexate; D035683:MicroRNAs; C542359:MIRN143 microRNA, human; C525067:MIR223, human
keywords: Biomarker; Blood; MicroRNA; PBMCs; Plasma; Psoriasis